Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Go back to Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
(NASDAQ: DNTH) Delayed: 94.34 +4.13 (4.58%)
Previous Close $90.21    52 Week High
Open $90.21    52 Week Low
Day High $94.70    P/E N/A 
Day Low $87.40    EPS
Volume 753,184